US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zeo ScientifiX Inc.

2.30

+0.07993.60%

Volume:12.60K

Turnover:30.17K

Market Cap:17.63M

PE:- -

High:2.43

Open:2.22

Low:2.20

Close:2.22

52wk High:3.32

52wk Low:1.20

Shares:7.66M

Float Shares:3.33M

Volume Ratio:6.45

T/O Rate:0.38%

Dividend:- -

Dividend Rate:- -

ROE:-2157.78%

ROA:-212.38%

PB:-12.39

PE(LYR):- -

Loading ...

Overview Company News Filings

ZEO Scientifix Inc. Files Initial Statement of Beneficial Ownership; John David Kisiday Named Chief Science Officer

ZEO Scientifix FY25 revenue rises 12.5% to USD 5.2 million

ZEO Scientifix Appoints Dr. John Kisiday as Chief Science Officer

ZEO Scientifix Awards Restricted Stock to CEO and CMO

ZEO Scientifix Partners with Cytora and Made Scientific to Launch Allogeneic Stem Cell Therapy in U.S

Cytora Therapeutics, Made Scientific, and Zeo Scientifix Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States

THOMSON REUTERS

ZEO Scientifix Inc. Terminates Chief Sales Officer Ron Borsheim

ZEO Scientifix Launches Clinical Trial Evaluating PPX for Musculoskeletal Joint Pathologies

ZEO Scientifix Inc. Reports 19.7% Increase in Revenues for Q3 2025, Driven by PPX™ Service Platform Sales

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZEOX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZEOX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZEOX\",,,,,undefined,":{"symbol":"ZEOX","market":"US","secType":"STK","nameCN":"Zeo ScientifiX Inc.","latestPrice":2.3,"timestamp":1771621200000,"preClose":2.2201,"halted":0,"volume":12602,"delay":15,"changeRate":0.03598936984820497,"floatShares":3329989,"shares":7664941,"eps":0,"marketStatus":"Market Closed","change":0.0799,"latestTime":"02-20 16:00:00 EST Delay","open":2.22,"high":2.4325,"low":2.2,"amount":30170.04,"amplitude":0.104725,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"exchange":"OTCQB","adjPreClose":2.2201,"volumeRatio":6.449335226148228},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZEOX\",,,,,undefined,":{"symbol":"ZEOX","floatShares":3329989,"roa":"-212.38%","roe":"-2157.78%","lyrEps":0,"volumeRatio":6.449335226148228,"shares":7664941,"dividePrice":0,"high":2.4325,"amplitude":0.104725,"preClose":2.2201,"low":2.2,"week52Low":1.2,"pbRate":"-12.39","psRate":"3.39","week52High":3.32,"institutionHeld":0,"latestPrice":2.3,"eps":0,"divideRate":0,"volume":12602,"delay":15,"open":2.22,"prevYearClose":2.71,"prevWeekClose":2.372,"prevMonthClose":2.6662,"prevQuarterClose":2.71,"fiveDayClose":2.27,"twentyDayClose":2.69,"sixtyDayClose":1.98},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZEOX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-09-16","symbol":"ZEOX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1726459200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-06-14","symbol":"ZEOX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1718337600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-03-18","symbol":"ZEOX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1710734400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-01-29","symbol":"ZEOX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1706504400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-28","symbol":"ZEOX","defaultRemindTime":1701181800000,"type":"split","dateTimestamp":1701147600000,"forFactor":200,"toFactor":1,"ratio":200}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZEOX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZEOX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZEOX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609514764","title":"ZEO Scientifix Inc. Files Initial Statement of Beneficial Ownership; John David Kisiday Named Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2609514764","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609514764?lang=en_us&edition=fundamental","pubTime":"2026-02-07 06:09","pubTimestamp":1770415770,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing identifies John David Kisiday as the beneficial owner, who serves as the company’s Chief Science Officer. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 06, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDLbMHn2n:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ZEO Scientifix Inc. Files Initial Statement of Beneficial Ownership; John David Kisiday Named Chief Science Officer","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZEOX"],"gpt_icon":0},{"id":"2607056096","title":"ZEO Scientifix FY25 revenue rises 12.5% to USD 5.2 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2607056096","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607056096?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:07","pubTimestamp":1769720878,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. reported full year  revenues of USD 5.2 million for the fiscal year ended October 31, 2025, representing a 12.5% increase. The company’s Higher Concentration Allogenic Aesthetic Biologics segment recorded revenues of USD 2.2 million, while the Lower Concentration Allogenic Aesthetic Biologics segment generated USD 1.4 million. ZEO Scientifix Inc. remains dependent on additional investment capital to fund ongoing operating expenses and research and development costs. The company stated that it does not expect recently issued accounting pronouncements to have a material effect on its financial condition or results of operations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDL1M9W9h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZEOX"],"gpt_icon":0},{"id":"2607723897","title":"ZEO Scientifix Appoints Dr. John Kisiday as Chief Science Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2607723897","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607723897?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:25","pubTimestamp":1769635559,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has appointed Dr. John D. Kisiday as its new Chief Science Officer, effective January 23, 2026. Dr. Kisiday brings nearly 30 years of experience in tissue engineering and regenerative medicine to the role.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDLbzlK73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZEOX"],"gpt_icon":0},{"id":"2605436971","title":"ZEO Scientifix Awards Restricted Stock to CEO and CMO","url":"https://stock-news.laohu8.com/highlight/detail?id=2605436971","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605436971?lang=en_us&edition=fundamental","pubTime":"2026-01-22 06:18","pubTimestamp":1769033901,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has granted 175,000 restricted shares of common stock each to Chief Executive Officer and Chief Financial Officer Ian Bothwell and Chief Medical Officer Dr. George Shapiro under the company's 2021 Incentive Stock Plan. The shares will vest in two installments: 50% after eight months from the award date and the remaining 50% after one year.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL1lP8jC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZEOX","BK4139"],"gpt_icon":0},{"id":"2601808543","title":"ZEO Scientifix Partners with Cytora and Made Scientific to Launch Allogeneic Stem Cell Therapy in U.S","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808543","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808543?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789032,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has announced a partnership with Cytora Therapeutics and Made Scientific to manufacture and commercialize Cytora’s allogeneic oral mucosal stem cell therapy in the United States. Under the collaboration, Cytora will provide manufacturing rights and continue clinical and regulatory development, Made Scientific will serve as the exclusive U.S. manufacturing partner with GMP-compliant facilities in Princeton, New Jersey, and ZEO Scientifix will act as the exclusive U.S. commercial partner, managing market access, distribution, and clinical site operations. The partnership aims to expand patient access to innovative stem cell therapies for non-healing diabetic foot ulcers and other indications, leveraging recent legislative developments in Florida and other states.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informa","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nNDLZZTdZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZEOX","BK4139"],"gpt_icon":0},{"id":"2601808562","title":"Cytora Therapeutics, Made Scientific, and Zeo Scientifix Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2601808562","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601808562?lang=en_us&edition=fundamental","pubTime":"2026-01-07 20:30","pubTimestamp":1767789000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nTUABCBTWP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZEOX"],"gpt_icon":0},{"id":"2588021259","title":"ZEO Scientifix Inc. Terminates Chief Sales Officer Ron Borsheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2588021259","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588021259?lang=en_us&edition=fundamental","pubTime":"2025-12-04 05:06","pubTimestamp":1764795973,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has announced the termination of Ron Borsheim as its Chief Sales Officer - Aesthetics, effective November 30, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL3wkzfG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZEOX","BK4139"],"gpt_icon":0},{"id":"2577304506","title":"ZEO Scientifix Launches Clinical Trial Evaluating PPX for Musculoskeletal Joint Pathologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2577304506","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577304506?lang=en_us&edition=fundamental","pubTime":"2025-10-23 20:30","pubTimestamp":1761222653,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has announced the launch of an IRB-approved clinical study titled \"Open-Label Prospective Longitudinal Clinical Trial to Evaluate the Safety and Potential Efficacy of PPX in Patients Suffering from Musculoskeletal Joint Pathologies Using Real-World Data to Monitor Patient Outcomes.\" The study aims to enroll up to 350 patients, with five clinics currently participating and seven patients enrolled to date. The results of the study have not yet been presented and will be collected as the trial progresses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ZEO Scientifix Inc. published the original content used to generate this news brief via ACCESS Newswire  on October 23, 2025, and is solely responsible for the informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251023:nNDL55S175:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZEOX"],"gpt_icon":0},{"id":"2567114208","title":"ZEO Scientifix Inc. Reports 19.7% Increase in Revenues for Q3 2025, Driven by PPX™ Service Platform Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2567114208","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567114208?lang=en_us&edition=fundamental","pubTime":"2025-09-16 04:16","pubTimestamp":1757967402,"startTime":"0","endTime":"0","summary":"ZEO Scientifix Inc. has released its financial results for the quarter ending July 31, 2025. The company reported revenues of $1.306 million for the three months ended July 31, 2025, representing an increase of $215,000 or 19.7% from the $1.091 million reported for the same period in 2024. This revenue growth was primarily driven by increased revenues from the PPX service platform, partially offset by a decline in sales of the company's allogenic aesthetic biologic products. ZEO Scientifix Inc. continues to focus on the development of innovative biological therapeutics for degenerative diseases and regenerative medicine, with products like Zofin and Patient Pure X being central to its offerings. The company remains dependent on additional investment capital to fund ongoing operating expenses and research and development efforts, as well as to conduct required clinical studies. Management anticipates that the company will continue to rely on external funding sources for the near future ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nNDL5wGcpN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZEOX"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}]}}